Drug Profile


Latest Information Update: 28 Aug 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzopyrans; Bronchodilators; Peripheral vasodilators
  • Mechanism of Action KATP channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hypertension
  • Discontinued Asthma

Most Recent Events

  • 28 Aug 1997 No-Development-Reported for Hypertension in Switzerland (Unknown route)
  • 28 Aug 1997 No-Development-Reported for Hypertension in United Kingdom (Unknown route)
  • 01 Nov 1996 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top